2Schillaci G,Pirro M. C reactive protein in hypertension:clinical significance and predictive value. [J]. Nutr Metab Cardiovase Dis, 2006, 16 (7) : 500-508.
3Ernst E. The role of fibrinogen as a cardiovascular risk factor [J]. Atherosclerosis, 1993,100( 1 ) : 1-12.
4Vermeer SE, Den Heijer T, Koudstaal PJ, et aI. Incidence and risk factors of silent brain infarcts in the population based Rotterdam Scan study[J]. Stroke,2003,34(2):392-396.
5McLean I.R,Thomas CE,Weintraub B, et al. Modulation of the physical state of cellular cholesteryl esters by 4, 4'- (isopropylidenedithio) bis(2,6-di-t-butylphenol) (probucol) [J].J Biol Chem, 1992,267 (17) : 12291-12298.
6Sawayama Y, Tatsukawa M, Kikuchi K, et al. Effect on carotid atherosclerosis of probucol plus levofloxacin for Chlamydia pneumoniae infection[J]. Infect Chem, 2007,13 (2) : 92-98.
7Mori Y,Wada H,Nagano Y,et al. Hypereoagulable state in the Watanabe heritable hyperlipidemic rabbit, an animal model for the progression of atherosclerosis. Effect of probucol on coagulation[J]. Thromb Haemost,1989,61(1) :140-143.
8Leibovitz E, Hazanov N,Frieman A,et al. Atorvastatin reduces fibrinogen levels in patients with severe hypercholesterolemia: additional evidence to support the anti-inflammatory effects of statins[J]. Isr Med Assoc, 2004,6 (8) : 456-459.
